Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 10, 2019

View Archived Issues

Cantargia announces start of CAN-10 development project for systemic sclerosis and myocarditis

Once-a-month oral contraceptive

Phase II data presented for KVD-001 in patients with diabetic macular edema

InMed receives CTA approval for phase I study of INM-755

First patient dosed in phase I study of BJ-001 in advanced or metastatic solid tumors

Discovery of novel inhaled JAK inhibitor for the treatment of respiratory diseases

DR-10601 shows promise for the treatment of type 2 diabetes and obesity in preclinical models

First preclinical data in DLBCL for BCMA-targeting 2 + 1 T-cell engager CC-93269

Innovent begins phase I study in China with anti-LAG-3 antibody IBI-110

CD3/CD7-IT causes clinical remission and rapid immune reconstitution in SR-aGvHD: phase I/II results

Quantitative and inducible modulation of the circadian clock with light using photocaged longdayisin

First-in-human data for novel oral multikinase inhibitor SKLB-1028 in R/R AML

With reduced toxicity, can HSCT make it to Hall of Fame?

AMR Centre patents new antibacterials

Vedanta initiates first-in-patient study of VE-800 with Opdivo in advanced or metastatic cancer

Guangzhou Henovcom Bioscience discloses ENPP2 inhibitors

Indivior selects CRO to conduct phase I study of INDV-2000

Nerviano Medical Sciences presents new IDH1 and/or IDH2 mutant inhibitors

Gilead Sciences identifies new benzamides for liver diseases

LAIMU synthesizes new compounds for allergy

FDA removes clinical hold on Abeona's phase III VIITAL study of EB-101

Sinovent studies small-molecule human URAT1 inhibitor XNW-3009 in phase I

Orca opens phase Ib study of TregGraft in hematologic malignancies